A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

CC-90011

CC-90011

DRUG

Cisplatin

Cisplatin

DRUG

Carboplatin

Carboplatin

DRUG

Etoposide

Etoposide

DRUG

Nivolumab

Nivolumab

Trial Locations (13)

13385

Local Institution - 102, Marseille

20089

Local Institution - 201, Rozzano (MI)

28041

Local Institution - 400, Madrid

28222

Local Institution - 406, Majadahonda

29010

Local Institution - 404, Málaga

40138

Local Institution - 200, Bologna

44800

Local Institution - 103, Saint-Herblain

46010

Local Institution - 405, Valencia

46026

Local Institution - 401, Valencia

60126

Local Institution - 203, Ancona

94805

Local Institution - 100, Villejuif

08035

Local Institution - 403, Barcelona

08916

Local Institution - 402, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY